You don’t need to lose weight to reverse prediabetes, study finds

For decades, the advice for anyone with prediabetes has been blunt: lose weight, or diabetes is coming. New research suggests that framing may be incomplete.

A study published in Nature Medicine found that roughly one in four participants in lifestyle programs were able to normalize their blood sugar without losing weight. More notably, the protective effect was equivalent to what people achieved through weight loss — meaning the metabolic improvement, not the number on the scale, appears to be what matters.

The research was led by Andreas L. Birkenfeld and Reiner Jumpertz-von Schwartzenberg at the University of Tübingen, with collaborators across Europe. According to the study, the mechanism centers on where fat is stored in the body rather than how much total fat a person carries.

Visceral fat — the kind that surrounds internal organs deep in the abdomen — promotes chronic inflammation and interferes with insulin signaling. When insulin doesn't work properly, blood glucose rises and prediabetes progresses. Subcutaneous fat, stored just beneath the skin, appears to operate differently: it can support healthier metabolic function and help insulin work more efficiently.

The finding reframes a clinical problem that has resisted simple solutions. Diabetes rates continue to rise globally despite decades of public health messaging about weight management. Many people with prediabetes struggle to lose weight and, discouraged, ultimately don't make the changes that might help. The new data suggests that metabolic improvement and fat redistribution may be achievable even without large-scale weight loss — and that focusing solely on the scale may have been the wrong target.

The researchers also identified a hormonal component that overlaps with the mechanism of GLP-1 drugs like Wegovy and Mounjaro. People who achieved remission without weight loss appeared to naturally boost their GLP-1 hormone system while reducing the influence of glucose-raising hormones — the same target those medications pursue pharmacologically.

On the practical side, the study points toward dietary patterns that may help shift fat distribution. Polyunsaturated fatty acids, common in Mediterranean-style diets rich in fish oil, olives, and nuts, were associated with reductions in visceral fat. Endurance exercise also lowered abdominal fat independent of overall weight change.

The researchers are careful not to dismiss weight loss entirely — losing weight still provides metabolic benefits. But the study suggests that for many patients who have struggled with conventional weight-loss programs, prioritizing blood sugar normalization and metabolic improvement may be a more achievable and equally effective goal.

For clinicians, the implication is a potentially significant shift in how prediabetes is counseled. Instead of defaulting to weight loss as the sole measurable target, tracking blood sugar improvements and encouraging fat redistribution through targeted nutrition and exercise could offer alternative strategies for patients who find conventional approaches inaccessible or unsustainable.

Notebook: The overlap with GLP-1 drug mechanisms is worth watching. If fat redistribution accounts for a meaningful portion of those drugs' metabolic benefits, it reframes what 'success' looks like in drug development — not just weight loss, but specific changes in where fat sits in the body.